Korea Investment CORP grew its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 18.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 139,831 shares of the medical equipment provider's stock after acquiring an additional 22,100 shares during the period. Korea Investment CORP owned about 0.06% of Hologic worth $10,080,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Public Sector Pension Investment Board increased its stake in Hologic by 13.7% in the 3rd quarter. Public Sector Pension Investment Board now owns 9,959 shares of the medical equipment provider's stock valued at $811,000 after purchasing an additional 1,200 shares in the last quarter. Erste Asset Management GmbH purchased a new position in shares of Hologic in the third quarter valued at $2,223,000. Paloma Partners Management Co acquired a new position in shares of Hologic during the 3rd quarter worth $582,000. Chevy Chase Trust Holdings LLC boosted its position in shares of Hologic by 13.9% in the 3rd quarter. Chevy Chase Trust Holdings LLC now owns 186,891 shares of the medical equipment provider's stock worth $15,224,000 after buying an additional 22,821 shares in the last quarter. Finally, HighTower Advisors LLC grew its stake in Hologic by 9.8% in the 3rd quarter. HighTower Advisors LLC now owns 22,603 shares of the medical equipment provider's stock valued at $1,832,000 after acquiring an additional 2,012 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.
Hologic Trading Up 1.9 %
NASDAQ:HOLX traded up $1.13 on Thursday, hitting $61.69. 4,596,048 shares of the stock were exchanged, compared to its average volume of 1,821,809. The stock has a fifty day moving average of $64.69 and a 200-day moving average of $72.88. The stock has a market cap of $13.84 billion, a PE ratio of 19.46, a PEG ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a fifty-two week low of $58.38 and a fifty-two week high of $84.67.
Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research analysts have recently weighed in on the stock. Leerink Partners cut shares of Hologic from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Needham & Company LLC cut Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target for the company. in a report on Monday, February 3rd. Stephens reaffirmed an "overweight" rating and set a $84.00 price objective on shares of Hologic in a research note on Thursday, February 6th. William Blair reissued an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Finally, BNP Paribas upgraded shares of Hologic to a "strong-buy" rating in a report on Tuesday, December 10th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $84.62.
View Our Latest Report on Hologic
Hologic Company Profile
(
Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Further Reading
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
